Anemia in patients with heart failure: Prevalence and prognostic role in a controlled trial and in clinical practice

Journal of Cardiac Failure

Volumn 11, Issue 2, 2005, Pages 91-98

  Maggioni, Aldo P ^a,g   Opasich, Cristina ^b   Anand, Inder ^c   Barlera, Simona ^d   Carbonieri, Emanuele ^e   Gonzini, Lucio ^a   Tavazzi, Luigi ^f   Latini, Roberto ^d   Cohn, Jay ^c  

^a Italian Association of Hospital Cardiologists   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e Ospedale Civile   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g ANMCO RESEARCH CENTER   (Italy)

Author keywords

Anemia; Epidemiology; Heart failure; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; INOTROPIC AGENT; VALSARTAN; VASODILATOR AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONFIDENCE INTERVAL; DEATH; FEMALE; FOLLOW UP; HEART FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

EID: 13944270337     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardfail.2004.05.004     Document Type: Article

References (39)

1. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., Barre P.E. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 28:1996;53-61
2. Al-Ahmad A., Rand W., Manjunath G., Konstam M.A., Salem D.N., Levey A.S., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 38:2001;955-962
3. Silverberg D.S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 37:2001;1775-1780
4. Hillege H.L., Girbes A., de Kam P.J., Boomsma F., de Zeeuw D., Charlesworth A., et al. Renal function, neuro-hormonal activation, and survival in patients with chronic heart failure. Circulation. 102:2000;203-210
5. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 35:2000;681-689
6. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 39:2002;1780-1786
7. Ezekowitz J.A., McAlister F.A., Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes. Insights from a cohort of 12065 patients with new-onset heart failure. Circulation. 107:2003;223-225
8. Kosiborod M., Smith G.L., Radford M.J., Foody J.M., Krumholz H.M. The prognostic importance of anemia in patients with heart failure. Am J Med. 114:2003;112-119
9. Mozaffarian D., Nye R., Levy W.C. Anemia predicts mortality in severe heart failure. The prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 41:2003;1933-1939
10. Silverberg D.S., Wexler D., Blum M., Keren G., Sheps D., Leibovitch E., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class and markedly reduces hospitalizations. J Am Coll Cardiol. 35:2000;1737-1744
11. Mancini D.M., Katz S.D., Lang C.C., LaManca J., Hudaihed A., Androne A.S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 107:2003;294-299
12. Opasich C., Tavazzi L., Lucci D., Gorini M., Albanese M.C., Cacciatore G., et al. Comparison of one-year outcome in women versus men with chronic congestive heart failure. Am J Cardiol. 86:2000;353-357
13. Opasich C., Rapezzi C., Lucci D., Gorini M., Pozzar F., Zanelli E., et al. Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). Am J Cardiol. 88:2001;382-387
14. Cohn J.N., Tognoni G., Glazer R.D., Spormann D., Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail. 5:1999;155-160
15. Cohn J.N., Tognoni G., Glazer R., Spormann D. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur J Heart Fail. 2:2000;439-446
16. Cohn J., Tognoni G. for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 345:2001;1667-1675
17. Task Force for the Diagnosis and Treatment of Chronic Heart Failure European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 22:2001;1527-1560
18. Joosten E., Pelermans W., Hiele M., Noyen J., Verhaeghe R., Boogaerts M.A. Prevalence and causes of anemia in a geriatric hospitalized population. Gerontology. 38:1992;111-117
19. Smieia M.J., Cook D.J., Hunt D.L., Ali M.A., Guyatt G.H. Recognizing and investigating iron-deficiency anemia in hospitalized elderly people. CMAJ. 155:1996;691-696
20. Wu W.C., Rathore S.S., Wang Y., Radford M., Krumholz H. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 345:2001;1230-1236
21. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241
22. Volpe M., Tritto C., Testa U., Rao M.A., Martucci R., Mirante A., et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol. 74:1994;468-473
23. Chatterjee B., Nydegger U., Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT1 antagonists. Eur J Heart Fail. 2:2000;393-398
24. Harnett J.D., Kent G.M., Foley R.N., Parfrey P.S. Cardiac function and hematocrit level. Am J Kidney Dis. 25:(Suppl. 1):1995;S3-S7
25. Glodberg N., Lundin A.P., Delano B., Friedman E.A., Stein R.A. Changes in left ventricular size, wall thickness and function in anemic patients treated with recombinant human erythropoietin. Am Heart J. 124:1992;424-427
26. Schunkert H., Hense H.W. A heart price to pay for anemia. Nephrol Dial Transplant. 16:2001;445-448
27. Michalsen A., Konig G., Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 80:1998;437-441
28. Feenstra J., Grobbee D.E., Jonkman F.A., Hoes A.W., Stricker B.H. Prevention of relapse in patients with congestive heart failure: the role of precipitating factors. Heart. 80:1998;432-436
29. Ramos Polledo V., Pita Fernandez S., De la Iglesia Martinez F., Pellicer Vazquez C., Nicolas Miguel R., et al. Etiology, clinical features, precipitating factors, type of ventricular dysfunction, length of stay and mortality of 305 patients admitted to hospital because of heart failure. Med Int. 17:2000;19-24
30. Sasaki T., Yanagitani Y., Kubo T., Matsuo H., Miyatake K. Precipitating factors in patients with repetitive exacerbation of chronic left heart failure. J Cardiol. 31:1998;215-222
31. Tsuyuki R.T., McKelvie R.S., Arnold J.M., Avezum A. Jr., Barretto A.C., Carvalho A.C., et al. Acute precipitants of congestive heart failure exacerbation. Arch Intern Med. 161:2001;2337-2342
32. Anand I.S., Chandrashekhar Y., Ferrari R., Poole-Wilson P.A., Harris P. Pathogenesis of edema in chronic severe anemia: studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Br Heart J. 70:1993;357-362
33. Anand I.S., Chandrashekhar Y., Wander G.S., Chawla L.S. Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol. 25:1995;1402-1407
34. Cowie M.R., Mosterd A., Wood D.A., Deckers J.W., Poole-Wilson P.A., Suttn G.C., et al. The epidemiology of heart failure. Eur Heart J. 18:1997;208-225
35. Senni M., Tribouilloy C.M., Rodeheffer R.J., Jacobsen S.J., Evans J.M., Bailey K.R., et al. Congestive heart failure in the community: a study of all incident cases in Olmsted county, Minnesota, in 1991. Circulation. 98:1998;2282-2289
36. Cohen-Solal A., Desnos M., Delahaye F., Emeriau J.P., Hanania G. for the Myocardiopathy and Heart Failure Working Group of the French Society of Cardiology. The National College of General Hospital Cardiologists and the French Geriatrics Society. A national survey of heart failure in French hospitals. Eur Heart J. 21:2000;763-769
37. Bellotti P., Badano L.P., Acquarone N., Griffo R., Lo Pinto G., Maggioni A.P., et al. Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure. The OSCUR Study. Eur Heart J. 22:2001;596-604
38. Chin M.H., Wang J.C., Zhang J.X., Sachs G.A., Lang R.M. Differences among geriatricians, general internists, and cardiologists in the care of patients with heart failure: a cautionary tale of quality assessment. J Am Geriatr Soc. 46:1998;1349-1354
39. Philbin E.F., Jenkins P.L. Differences between patients with heart failure treated by cardiologists, internists, family physicians and other physicians: analysis of a large statewide database. Am Heart J. 139:2000;491-496